Kura Oncology Achieves $9.1M in Ziftomenib Revenue After Two Full Launch Quarters

Two quarters into commercialization, Kura Oncology's KOMZIFTI (ziftomenib) is generating measurable traction in relapsed/refractory NPM1-mutant AML, a signal that contract manufacturers and API suppliers supporting the menin inhibitor class should read carefully against their own capacity planning cycles. Net product revenue reached $9.1 million in Q2 2026, a 57% sequential increase, with approximately 115 new patient starts, up 35% from Q1.

KOMZIFTI secured majority share of new patient starts within the R/R NPM1-m AML menin inhibitor class during its second full quarter on market. Adoption is broadening across both academic and community treatment centers, with repeat prescribing rates rising alongside physician-directed combination use with established standards of care. For supply chain leads, that combination use pattern, ziftomenib alongside venetoclax/azacitidine or intensive chemotherapy, introduces multi-agent demand forecasting complexity that single-agent launch models do not capture.

Clinical data presented at EHA 2026 from the KOMET-007 study reinforce the commercial trajectory. In 99 newly diagnosed NPM1-m or KMT2A-r AML patients, 600 mg ziftomenib plus intensive chemotherapy (7+3) produced composite complete remission rates of 96% and 90%, respectively, with 12-month overall survival rates of 94% and 71%. No new safety signals were identified, and median OS was not reached in either molecular subgroup. A concurrent Blood publication reported an 87% ORR and 70% CRc rate in venetoclax-naïve R/R patients receiving ziftomenib plus venetoclax and azacitidine, with 75% of composite complete responders achieving central MRD negativity.

These results are directly informing the registrational KOMET-017 frontline program, which is actively enrolling. If frontline indications are pursued and eventually approved, the addressable patient population expands substantially, Kura cites a $7 billion total addressable market. For QA directors at CDMOs or API manufacturers already in the oncology space, that scale shift warrants early dialogue on process validation scope and batch record infrastructure, particularly given the combination regimen complexity flagged in the clinical data.

Kura reported $519.0 million in cash, cash equivalents, and short-term investments, plus $180 million in anticipated collaboration payments, a runway that supports continued registrational investment without near-term financing pressure. The darlifarnib program, targeting RCC and KRAS-mutated solid tumors, adds a second precision combination asset to the pipeline, though it remains at an earlier clinical stage.

The pace at which KOMET-017 enrollment completes and interim data mature will set the timeline for any supplemental regulatory submission, making that program the near-term checkpoint for manufacturers and regulatory affairs teams tracking ziftomenib's trajectory beyond the current approved indication.

Source: Kura Oncology via GlobeNewswire, August 12, 2026. Management webcast and conference call held same day at 4:30 p.m. ET / 1:30 p.m. PT.